Coegin Pharma AB
Coegin Pharma AB, a biotechnology company, engages in developing peptide-based products for hair growth and skin pigmentation in Sweden. The company develops Follicopeptide, a peptide designed to enhance hair growth; and NPP-4, a natural pigmentation peptide 4 works by facilitating the transport of melanin to the skin, mimicking the natural process that occurs during sun exposure or tanning beds.… Read more
Coegin Pharma AB (7Z6) - Total Liabilities
Latest total liabilities as of September 2025: €2.24 Million EUR
Based on the latest financial reports, Coegin Pharma AB (7Z6) has total liabilities worth €2.24 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Coegin Pharma AB - Total Liabilities Trend (2021–2024)
This chart illustrates how Coegin Pharma AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Coegin Pharma AB Competitors by Total Liabilities
The table below lists competitors of Coegin Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canasil Resources Inc.
V:CLZ
|
Canada | CA$522.09K |
|
General Commercial & Industrial S.A
AT:GEBKA
|
Greece | €8.64 Million |
|
Polygiene AB
ST:POLYG
|
Sweden | Skr24.66 Million |
|
Canada Silver Cobalt Works Inc
OTCQB:CCWOF
|
USA | $5.09 Million |
|
Snack Empire Holdings Limited
PINK:SNEHF
|
USA | $9.58 Million |
|
Anvi Global Holdings, Inc.
OTCQB:ANVI
|
USA | $2.32 Million |
|
Grand House Mulia Pt
JK:HOMI
|
Indonesia | Rp61.99 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Coegin Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Coegin Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Coegin Pharma AB (2021–2024)
The table below shows the annual total liabilities of Coegin Pharma AB from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €1.78 Million | -79.50% |
| 2023-12-31 | €8.68 Million | +5.45% |
| 2022-12-31 | €8.23 Million | -19.80% |
| 2021-12-31 | €10.26 Million | -- |